Bernd Schnabl

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5402112/publications.pdf

Version: 2024-02-01

140 papers	14,362 citations	29994 54 h-index	21474 114 g-index
145 all docs	145 docs citations	145 times ranked	14863 citing authors

#	Article	IF	Citations
1	A semiparametric model for betweenâ€subject attributes: Applications to betaâ€diversity of microbiome data. Biometrics, 2022, 78, 950-962.	0.8	5
2	Aryl Hydrocarbon Receptor Deficiency in Intestinal Epithelial Cells Aggravates Alcohol-Related Liver Disease. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 233-256.	2.3	26
3	Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis. Clinical Gastroenterology and Hepatology, 2022, 20, e289-e297.	2.4	17
4	Role of the Gut Microbiota in Parenteral Nutritionâ€“Associated Liver Disease: From Current Knowledge to Future Opportunities. Journal of Nutrition, 2022, 152, 377-385.	1.3	7
5	Bacteriophages and their potential for treatment of gastrointestinal diseases. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 135-144.	8.2	46
6	Machine Learning Applied to Omics Datasets Predicts Mortality in Patients with Alcoholic Hepatitis. Metabolites, 2022, 12, 41.	1.3	6
7	Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice. Hepatology International, 2022, 16, 359-370.	1.9	15
8	Gut Microbiome and Alcohol-associated Liver Disease. Journal of Clinical and Experimental Hepatology, 2022, 12, 1349-1359.	0.4	12
9	Roles for the mycobiome in liver disease. Liver International, 2022, 42, 729-741.	1.9	16
10	Liver specific, systemic and genetic contributors to alcohol-related liver disease progression. Zeitschrift Fur Gastroenterologie, 2022, 60, 36-44.	0.2	2
11	The fecal mycobiome in non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 76, 788-799.	1.8	66
12	Development of a Robotic Shear Wave Elastography System for Noninvasive Staging of Liver Disease in Murine Models. Hepatology Communications, 2022, 6, 1827-1839.	2.0	5
13	Immune Response of an Oral Enterococcus faecalis Phage Cocktail in a Mouse Model of Ethanol-Induced Liver Disease. Viruses, 2022, 14, 490.	1.5	6
14	RORÎ³t phosphorylation protects against TÂcell-mediated inflammation. Cell Reports, 2022, 38, 110520.	2.9	12
15	Effect of rifaximin on infections, acuteâ€onâ€chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFAâ€AH). Liver International, 2022, 42, 1109-1120.	1.9	20
16	Intestinal virome in patients with alcohol use disorder and after abstinence. Hepatology Communications, 2022, 6, 2058-2069.	2.0	18
17	Lipidomics for the Prediction of Progressive Liver Disease in Patients with Alcohol Use Disorder. Metabolites, 2022, 12, 433.	1.3	6
18	Promises of microbiome-based therapies. Journal of Hepatology, 2022, 76, 1379-1391.	1.8	33

#	Article	IF	Citations
19	Liver cirrhosis and immune dysfunction. International Immunology, 2022, 34, 455-466.	1.8	12
20	The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice. Translational Research, 2021, 227, 1-14.	2.2	13
21	Microbial Products and Metabolites Contributing to Alcoholâ€Related Liver Disease. Molecular Nutrition and Food Research, 2021, 65, e2000023.	1.5	13
22	The gut mycobiome: a novel player in chronic liver diseases. Journal of Gastroenterology, 2021, 56, 1-11.	2.3	22
23	Targeting pathobionts for the treatment of alcoholâ€associated liver disease. Liver International, 2021, 41, 239-240.	1.9	1
24	Targeting the gut-liver-immune axis to treat cirrhosis. Gut, 2021, 70, 982-994.	6.1	88
25	Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. Cell Metabolism, 2021, 33, 21-32.	7.2	98
26	Gut microbiome, liver immunology, and liver diseases. Cellular and Molecular Immunology, 2021, 18, 4-17.	4.8	182
27	Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma. Cancer Discovery, 2021, 11, 1248-1267.	7.7	117
28	Microbiome of the Aerodigestive Tract in Health and Esophageal Disease. Digestive Diseases and Sciences, 2021, 66, 12-18.	1.1	10
29	Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 891-920.	2.3	17
30	New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 2021, 41, 087-102.	1.8	10
31	Serum Acylcarnitines Associated with High Short-Term Mortality in Patients with Alcoholic Hepatitis. Biomolecules, 2021, 11, 281.	1.8	7
32	Fungiâ€“Bacteria Correlation in Alcoholic Hepatitis Patients. Toxins, 2021, 13, 143.	1.5	12
33	Gut dysbiosis as a driver in alcohol-induced liver injury. JHEP Reports, 2021, 3, 100220.	2.6	46
34	An Introduction to Next Generation Sequencing Bioinformatic Analysis in Gut Microbiome Studies. Biomolecules, 2021, 11, 530.	1.8	62
35	Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsyâ€proven nonâ€alcoholic fatty liver disease. Liver International, 2021, 41, 1576-1591.	1.9	11
36	Colesevelam Reduces Ethanol-Induced Liver Steatosis in Humanized Gnotobiotic Mice. Cells, 2021, 10, 1496.	1.8	6

#	Article	IF	Citations
37	The microbiota in cirrhosis and its role in hepatic decompensation. Journal of Hepatology, 2021, 75, S67-S81.	1.8	107
38	Dynamic Changes of the Fungal Microbiome in Alcohol Use Disorder. Frontiers in Physiology, 2021, 12, 699253.	1.3	45
39	Intestinal virome and therapeutic potential of bacteriophages in liver disease. Journal of Hepatology, 2021, 75, 1465-1475.	1.8	28
40	Intestinal Î±1-2-Fucosylation Contributes to Obesity and Steatohepatitis in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 293-320.	2.3	14
41	Update on the Role of the Gut Microbiota on Alcohol-Associated Liver Disease. Gastroenterology and Hepatology, 2021, 17, 381-383.	0.2	0
42	Integrative Analysis of Metabolome and Microbiome in Patients with Progressive Alcohol-Associated Liver Disease. Metabolites, 2021, 11, 766.	1.3	3
43	Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease. International Journal of Molecular Sciences, 2021, 22, 12687.	1.8	10
44	CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease. Nature Communications, 2021, 12, 7172.	5.8	22
45	Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. Hepatology, 2020, 71, 522-538.	3.6	151
46	Intestinal and hepatic microbiota changes associated with chronic ethanol administration in mice. Gut Microbes, 2020, 11, 265-275.	4.3	31
47	The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. Journal of Hepatology, 2020, 72, 391-400.	1.8	119
48	A Novel Mouse Model of Acuteâ€onâ€Chronic Cholestatic Alcoholic Liver Disease: A Systems Biology Comparison With Human Alcoholic Hepatitis. Alcoholism: Clinical and Experimental Research, 2020, 44, 87-101.	1.4	8
49	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. Gut, 2020, 69, 764-780.	6.1	112
50	Changes in the fecal bacterial microbiota associated with disease severity in alcoholic hepatitis patients. Gut Microbes, 2020, 12, 1785251.	4.3	60
51	Transcriptomic Profiling Identifies Novel Hepatic and Intestinal Genes Following Chronic Plus Binge Ethanol Feeding in Mice. Digestive Diseases and Sciences, 2020, 65, 3592-3604.	1.1	11
52	Persistent SARS-CoV-2 RNA Positive in Feces but Negative in Breastmilk: A Case Report of COVID-19 in a Breastfeeding Patient. Frontiers in Medicine, 2020, 7, 562700.	1.2	8
53	Functional Microbiomics Reveals Alterations of the Gut Microbiome and Host Coâ€Metabolism in Patients With Alcoholic Hepatitis. Hepatology Communications, 2020, 4, 1168-1182.	2.0	22
54	Microbiota and Fatty Liver Diseaseâ€"the Known, the Unknown, and the Future. Cell Host and Microbe, 2020, 28, 233-244.	5.1	115

#	Article	IF	Citations
55	Multicenter Analysis of Liver Injury Patterns and Mortality in COVID-19. Frontiers in Medicine, 2020, 7, 584342.	1.2	22
56	Skin wound closure delay in metabolic syndrome correlates with SCF deficiency in keratinocytes. Scientific Reports, 2020, 10, 21732.	1.6	12
57	Functional Microbial Responses to Alcohol Abstinence in Patients With Alcohol Use Disorder. Frontiers in Physiology, 2020, 11, 370.	1.3	11
58	Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?. Physiology, 2020, 35, 261-274.	1.6	28
59	Alcoholic-Hepatitis, Links to Brain and Microbiome: Mechanisms, Clinical and Experimental Research. Biomedicines, 2020, 8, 63.	1.4	15
60	Differential Activation of Unconventional T Cells, Including iNKT Cells, in Alcoholâ€Related Liver Disease. Alcoholism: Clinical and Experimental Research, 2020, 44, 1061-1074.	1.4	12
61	Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease. Gastroenterology, 2020, 159, 1839-1852.	0.6	103
62	Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans. Gut Microbes, 2020, 12, 1782157.	4.3	83
63	Deficiency of Intestinal Î±1â€2â€Fucosylation Exacerbates Ethanolâ€Induced Liver Disease in Mice. Alcoholism: Clinical and Experimental Research, 2020, 44, 1842-1851.	1.4	11
64	Intestinal Virome in Patients With Alcoholic Hepatitis. Hepatology, 2020, 72, 2182-2196.	3.6	74
65	Cytolysinâ€positive Enterococcus faecalis is not increased in patients with nonâ€alcoholic steatohepatitis. Liver International, 2020, 40, 860-865.	1.9	29
66	High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLD. Hepatology Communications, 2020, 4, 681-695.	2.0	28
67	From intestinal dysbiosis to alcohol-associated liver disease. Clinical and Molecular Hepatology, 2020, 26, 595-605.	4.5	24
68	Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice. World Journal of Gastroenterology, 2020, 26, 4933-4944.	1.4	8
69	YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15184-15193.	3.3	24
70	Serum and Fecal Oxylipins in Patients with Alcohol-Related Liver Disease. Digestive Diseases and Sciences, 2019, 64, 1878-1892.	1.1	35
71	Intestinal iNKT cells migrate to liver and contribute to hepatocyte apoptosis during alcoholic liver disease. American Journal of Physiology - Renal Physiology, 2019, 316, G585-G597.	1.6	23
72	Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation. Journal of Internal Medicine, 2019, 286, 32-40.	2.7	111

#	Article	IF	Citations
73	Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either. American Journal of Physiology - Renal Physiology, 2019, 316, G563-G573.	1.6	54
74	Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. Translational Research, 2019, 209, 22-38.	2.2	51
75	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature, 2019, 575, 505-511.	13.7	493
76	Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut, 2019, 68, 359-370.	6.1	236
77	Antimicrobial proteins: intestinal guards to protect against liver disease. Journal of Gastroenterology, 2019, 54, 209-217.	2.3	33
78	Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. Gut, 2019, 68, 1504-1515.	6.1	202
79	Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for Clinicians. Clinical Gastroenterology and Hepatology, 2019, 17, 218-230.	2.4	187
80	Microbiome as a therapeutic target in alcohol-related liver disease. Journal of Hepatology, 2019, 70, 260-272.	1.8	170
81	Intestinal Microbiota Mediates the Susceptibility to Polymicrobial Sepsisâ€Induced Liver Injury by Granisetron Generation in Mice. Hepatology, 2019, 69, 1751-1767.	3.6	102
82	Gut microbiota, fatty liver disease, and hepatocellular carcinoma. Liver Research, 2018, 2, 43-51.	0.5	64
83	Gut microbiota mediates diurnal variation of acetaminophen induced acute liver injury in mice. Journal of Hepatology, 2018, 69, 51-59.	1.8	178
84	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. Journal of Hepatology, 2018, 69, 396-405.	1.8	144
85	Risk factors for progression of and treatment options for NAFLD in children. Clinical Liver Disease, 2018, 11, 11-15.	1.0	19
86	Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1Î± Transactivation in Steatohepatitis. Cell Metabolism, 2018, 27, 339-350.e3.	7.2	62
87	Intestinal dysbiosis and permeability: the yin and yang in alcohol dependence and alcoholic liver disease. Clinical Science, 2018, 132, 199-212.	1.8	78
88	Î²-Hydroxybutyrate protects from alcohol-induced liver injury via a Hcar2-cAMP dependent pathway. Journal of Hepatology, 2018, 69, 687-696.	1.8	48
89	Immunoglobulin A and liver diseases. Journal of Gastroenterology, 2018, 53, 691-700.	2.3	38
90	Pyroptosis by caspase11/4â€gasderminâ€Ð pathway in alcoholic hepatitis in mice and patients. Hepatology, 2018, 67, 1737-1753.	3.6	165

#	Article	IF	Citations
91	Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with nonâ€alcoholic fatty liver disease. British Journal of Pharmacology, 2018, 175, 469-484.	2.7	116
92	Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology, 2018, 67, 2150-2166.	3.6	189
93	Check your microbiota when taking the drug. Hepatology, 2018, 67, 18-20.	3.6	2
94	Reply to: â€œFinding fibroblast growth factor 19 during cholestasis: Does x mark the spot?. Journal of Hepatology, 2018, 69, 1400-1401.	1.8	0
95	Complex Network of NKT Cell Subsets Controls Immune Homeostasis in Liver and Gut. Frontiers in Immunology, 2018, 9, 2082.	2.2	35
96	New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature, 2018, 560, 198-203.	13.7	722
97	The gutâ€“liver axis and the intersection with the microbiome. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 397-411.	8.2	905
98	Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metabolism, 2017, 25, 1054-1062.e5.	7.2	748
99	Lamin Deficiency in the Liver Sets the Stage for Nonalcoholic Steatohepatitis Development in Males. Cellular and Molecular Gastroenterology and Hepatology, 2017, 4, 441-442.	2.3	2
100	Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nature Communications, 2017, 8, 837.	5.8	174
101	Weight Loss Decreases Magnetic Resonance Elastography Estimated Liver Stiffness in Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2017, 15, 463-464.	2.4	29
102	Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood. Hepatology, 2017, 65, 475-490.	3.6	91
103	Intestinal fungi contribute to development of alcoholic liver disease. Journal of Clinical Investigation, 2017, 127, 2829-2841.	3.9	336
104	Liver capsule: Mechanisms of alcoholic hepatitis. Hepatology, 2016, 64, 276-276.	3.6	9
105	Does the Intestinal Microbiota Explain Differences in the Epidemiology of Liver Disease between East and West?. Inflammatory Intestinal Diseases, 2016, 1, 3-8.	0.8	4
106	Bidirectional Communication between Liver and Gut during Alcoholic Liver Disease. Seminars in Liver Disease, 2016, 36, 331-339.	1.8	84
107	Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. American Journal of Physiology - Renal Physiology, 2016, 311, G1018-G1036.	1.6	64
108	Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity. American Journal of Physiology - Renal Physiology, 2016, 310, G310-G322.	1.6	38

#	Article	IF	Citations
109	Microbiota and Alcoholic Liver Disease. Alcoholism: Clinical and Experimental Research, 2016, 40, 1791-1792.	1.4	8
110	Fast-Track Clearance of Bacteria from the Liver. Cell Host and Microbe, 2016, 20, 1-2.	5.1	39
111	Acute-on-chronic liver failure in cirrhosis. Nature Reviews Disease Primers, 2016, 2, 16041.	18.1	320
112	Genetic Loss of Immunoglobulin A Does Not Influence Development of Alcoholic Steatohepatitis in Mice. Alcoholism: Clinical and Experimental Research, 2016, 40, 2604-2613.	1.4	19
113	Editorsâ€™ Introduction to the NAFLD and NASH Special Issue. Digestive Diseases and Sciences, 2016, 61, 1211-1213.	1.1	6
114	Staging of fibrosis in experimental non-alcoholic steatohepatitis by quantitative molecular imaging in rat models. Nuclear Medicine and Biology, 2016, 43, 179-187.	0.3	9
115	Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation. Cell Host and Microbe, 2016, 19, 227-239.	5.1	284
116	Microbiota Protects Mice Against Acute Alcoholâ€Induced Liver Injury. Alcoholism: Clinical and Experimental Research, 2015, 39, 2313-2323.	1.4	92
117	The Gut Microbiota and Liver Disease. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 275-284.	2.3	166
118	Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nature Medicine, 2015, 21, 159-165.	15.2	562
119	Effect of Weight Loss on Magnetic Resonance Imaging Estimation of Liver Fat and Volume in Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2015, 13, 561-568.e1.	2.4	128
120	Methods to determine intestinal permeability and bacterial translocation during liver disease. Journal of Immunological Methods, 2015, 421, 44-53.	0.6	199
121	Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1069-1076.	1.4	55
122	Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. Journal of Hepatology, 2015, 63, 1272-1284.	1.8	463
123	Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. FASEB Journal, 2015, 29, 1043-1055.	0.2	156
124	Supplementation of Saturated Long-Chain Fatty Acids Maintains Intestinal Eubiosis and Reduces Ethanol-induced Liver Injury in Mice. Gastroenterology, 2015, 148, 203-214.e16.	0.6	266
125	Host-Microbiome Interactions in Alcoholic Liver Disease. Gut and Liver, 2014, 8, 237-241.	1.4	73
126	Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. Journal of Hepatology, 2014, 60, 1310-1324.	1.8	685

#	Article	IF	Citations
127	Interactions Between the Intestinal Microbiome and Liver Diseases. Gastroenterology, 2014, 146, 1513-1524.	0.6	806
128	Transplanting a fibrogenic microbiota. Hepatology, 2014, 59, 1660-1661.	3.6	1
129	Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids. Journal of Hepatology, 2014, 60, 1259-1267.	1.8	28
130	Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls. Gastroenterology Research and Practice, 2013, 2013, 1-8.	0.7	42
131	Fibroblast growth factor inducible 14 as potential target in patients with alcoholic hepatitis. Gut, 2013, 62, 335-336.	6.1	0
132	Linking intestinal homeostasis and liver disease. Current Opinion in Gastroenterology, 2013, 29, 264-270.	1.0	71
133	Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology, 2013, 58, 108-119.	3.6	187
134	Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. Journal of Hepatology, 2012, 56, 1283-1292.	1.8	289
135	Toll-Like Receptor 2â€“Mediated Intestinal Injury and Enteric Tumor Necrosis Factor Receptor I Contribute to Liver Fibrosis in Mice. Gastroenterology, 2012, 143, 1330-1340.e1.	0.6	108
136	Origin of myofibroblasts in liver fibrosis. Fibrogenesis and Tissue Repair, 2012, 5, S17.	3.4	99
137	Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology, 2011, 53, 96-105.	3.6	636
138	Peroxisome proliferatorâ€activated receptorâ€Î´ as emerging target in liver disease. Drug Development Research, 2010, 71, 106-111.	1.4	0
139	A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells. Biochemical and Biophysical Research Communications, 2008, 375, 210-214.	1.0	36
140	What is the potential role of antifibrotic agents for the treatment of liver disease?. Nature Reviews Gastroenterology & Hepatology, 2008, 5, 496-497.	1.7	14